Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Tempus AI assembles genetic and clinical data on cancer patients and sells access to it.
The company runs genetic tests for clinics and simultaneously accumulates the link between mutation, treatment given and outcome. Separately many hold such information; together almost nobody does, because clinical records and genomic data sit in different systems.
That database is the asset: pharmaceutical companies buy access to it to select patients for trials and to support the use of their drugs. The testing itself remains low-margin and depends on insurer reimbursement. Risks: regulation of medical data use, competition from laboratories and losses during the growth phase. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Tempus AI, Inc. (TEM) is a company in the Technology sector; its shares trade on Nasdaq.
The price of Tempus AI, Inc. (TEM) on November 2, 2026 is 80.75 $, +11.81 % on the day. Over 52 weeks the stock traded between 40.77 $ and 97.25 $; the price now sits 71 % of the way up that range. Over the past year the price changed by −22.61 %. Market capitalization is 12.39 billion $, rank 8 among 47 stocks of the same industry with a known capitalization.
Tempus AI, Inc. trades on Nasdaq under the ticker TEM. The company belongs to the Technology sector. The trading history on this page starts on 14 June 2024.
Over the past 52 weeks TEM has traded between 40.77 $ and 97.25 $. As of 2 November 2026 the price stood 53.75 % of the way from the 52-week low to the high.
Over one year TEM shares fell 22.61 %; over six months they rose 30.71 %. Volatility over 90 days is 86.30 %. Dividends are not included: this is price change only, as of 2 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 8.6, above the sector median of 3.4. Price to book is 27.8, above the sector median of 3.4. Calculated from reports for the period ending 30 June 2026.
Tempus AI, Inc. reported revenue of 1.4B $ and a net loss of 254M $ over the last four quarters. Net margin is −17.77 %. Revenue changed by +50.43 % year over year. Earnings per share are −1.44 $. Market capitalisation is 12.4B $.
TEM has a return on equity of −57.18 %, below the sector median of 2.27 %. Return on assets is −10.75 %, below the sector median of 0.67 %. Operating margin is −19.76 %, below the sector median of 1.05 %.